These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

140 related articles for article (PubMed ID: 32216457)

  • 1. Subcutaneous sumatriptan reduces cilostazol induced headache in migraine patients.
    Falkenberg K; Bjerg HR; Olesen J
    Cephalalgia; 2020 Jul; 40(8):842-850. PubMed ID: 32216457
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cilostazol induced migraine does not respond to sumatriptan in a double blind trial.
    Falkenberg K; Dunga BÓÁ; Guo S; Ashina M; Olesen J
    J Headache Pain; 2018 Feb; 19(1):11. PubMed ID: 29396788
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Toward a pragmatic migraine model for drug testing: I. Cilostazol in healthy volunteers.
    Hansen EK; Guo S; Ashina M; Olesen J
    Cephalalgia; 2016 Feb; 36(2):172-8. PubMed ID: 25934317
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pre-treatment with sumatriptan for cilostazol induced headache in healthy volunteers.
    Falkenberg K; Olesen J
    J Headache Pain; 2018 Aug; 19(1):71. PubMed ID: 30120600
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Sumatriptan Does Not Antagonize CGRP-Induced Symptoms in Healthy Volunteers.
    Falkenberg K; Rønde Bjerg H; Yamani N; Olesen J
    Headache; 2020 Apr; 60(4):665-676. PubMed ID: 31944310
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Towards a pragmatic human migraine model for drug testing: 2. Isosorbide-5-mononitrate in healthy individuals.
    Hansen EK; Olesen J
    Cephalalgia; 2017 Jan; 37(1):11-19. PubMed ID: 26924839
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Induction of migraine-like headache, but not aura, by cilostazol in patients with migraine with aura.
    Butt JH; Rostrup E; Hansen AS; Lambertsen KL; Kruuse C
    Brain; 2018 Oct; 141(10):2943-2951. PubMed ID: 30137217
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Promethazine plus sumatriptan in the treatment of migraine: a randomized clinical trial.
    Asadollahi S; Heidari K; Vafaee R; Forouzanfar MM; Amini A; Shahrami A
    Headache; 2014 Jan; 54(1):94-108. PubMed ID: 24182419
    [TBL] [Abstract][Full Text] [Related]  

  • 9. DFN-02 (Sumatriptan 10 mg With a Permeation Enhancer) Nasal Spray vs Placebo in the Acute Treatment of Migraine: A Double-Blind, Placebo-Controlled Study.
    Lipton RB; Munjal S; Brand-Schieber E; Rapoport AM
    Headache; 2018 May; 58(5):676-687. PubMed ID: 29878341
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Transdermal sumatriptan for acute treatment of migraineurs with baseline nausea.
    Schulman EA
    Headache; 2012 Feb; 52(2):204-12. PubMed ID: 22229837
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A Randomized Trial of Ketorolac vs. Sumatripan vs. Placebo Nasal Spray (KSPN) for Acute Migraine.
    Rao AS; Gelaye B; Kurth T; Dash PD; Nitchie H; Peterlin BL
    Headache; 2016 Feb; 56(2):331-40. PubMed ID: 26840902
    [TBL] [Abstract][Full Text] [Related]  

  • 12. AVP-825 breath-powered intranasal delivery system containing 22 mg sumatriptan powder vs 100 mg oral sumatriptan in the acute treatment of migraines (The COMPASS study): a comparative randomized clinical trial across multiple attacks.
    Tepper SJ; Cady RK; Silberstein S; Messina J; Mahmoud RA; Djupesland PG; Shin P; Siffert J
    Headache; 2015 May; 55(5):621-35. PubMed ID: 25941016
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The Efficacy of Propofol vs. Subcutaneous Sumatriptan for Treatment of Acute Migraine Headaches in the Emergency Department: A Double-Blinded Clinical Trial.
    Moshtaghion H; Heiranizadeh N; Rahimdel A; Esmaeili A; Hashemian H; Hekmatimoghaddam S
    Pain Pract; 2015 Nov; 15(8):701-5. PubMed ID: 25040321
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Randomized, double-blind, crossover study comparing DFN-11 injection (3 mg subcutaneous sumatriptan) with 6 mg subcutaneous sumatriptan for the treatment of rapidly-escalating attacks of episodic migraine.
    Cady RK; Munjal S; Cady RJ; Manley HR; Brand-Schieber E
    J Headache Pain; 2017 Dec; 18(1):17. PubMed ID: 28176235
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy of subcutaneous sumatriptan in the acute treatment of early-morning migraine: a placebo-controlled trial. Early-Morning Migraine Sumatriptan Study Group.
    Bousser MG; D'Allens H; Richard A
    J Intern Med; 1993 Aug; 234(2):211-6. PubMed ID: 8393474
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A double-blind study of subcutaneous dihydroergotamine vs subcutaneous sumatriptan in the treatment of acute migraine.
    Winner P; Ricalde O; Le Force B; Saper J; Margul B
    Arch Neurol; 1996 Feb; 53(2):180-4. PubMed ID: 8639069
    [TBL] [Abstract][Full Text] [Related]  

  • 17. An open-label trial of a sumatriptan auto-injector for migraine in patients currently treated with subcutaneous sumatriptan.
    Landy SH; Tepper SJ; Wein T; Schweizer E; Ramos E
    Headache; 2013 Jan; 53(1):118-125. PubMed ID: 23148799
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Subcutaneous sumatriptan during the migraine aura. Sumatriptan Aura Study Group.
    Bates D; Ashford E; Dawson R; Ensink FB; Gilhus NE; Olesen J; Pilgrim AJ; Shevlin P
    Neurology; 1994 Sep; 44(9):1587-92. PubMed ID: 7936279
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The efficacy and safety of subcutaneous sumatriptan in the acute treatment of menstrual migraine. The Sumatriptan Menstrual Migraine Study Group.
    Facchinetti F; Bonellie G; Kangasniemi P; Pascual J; Shuaib A
    Obstet Gynecol; 1995 Dec; 86(6):911-6. PubMed ID: 7501338
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The efficacy of subcutaneous sumatriptan in the treatment of recurrence of migraine headache.
    Cull RE; Price WH; Dunbar A
    J Neurol Neurosurg Psychiatry; 1997 May; 62(5):490-5. PubMed ID: 9153607
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.